When associated with other inhibitors such as fulvestrant, taselisib has demonstrated a higher antitumoral response in HER-2 negative and ER positive breast cancers with PIK3CA mutations if compared with the wild type [122]. This evidence concerns the gene ERBB2 and breast carcinoma.